MT204
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
|
IL-2 0.58 nM (Kd) |
MT204 (1-100 μg/mL, 4 days) dose-dependently inhibits proliferation and IFN-γ secretion in rhesus PBMCs stimulated by the mitogen concavalin A[1].
MT204 can block CD25-bound IL-2 on high-affinity IL-2 receptors with a kd of 0.58 nM[1][2].
MT204 (5 h) dose dependently reduces the IL-2 inducible cell surface expression of the alpha subunit of IL-4 receptor (CD124) in CTLL-2 cells[2].
MT204 (5 days) inhibits IL-2-induced proliferation of NKL cells and T cells with IC50 s of approximately 1.3 nM and 0.21 nM, respectively[2].
MT204 (15 min) potently antagonizes downstream signaling of IL-2 at sub-nanomolar concentrations, significantly reducing cellular pY-STAT3 levels stimulated by IL-2 in Primary human lymphocytes[2].
MT204 significantly inhibits IL-2 induced proliferation independently of CD25 expression levels in NKL cells, T cells and all NK cells with IC50 s of 0.35-0.36 nM, 0.33 nM, and 0.1-0.13 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | Note | Plasma Concentration | T1/2 |
|---|---|---|---|---|---|
| Rhesus monkey | 2, 10, 50 or repeat 50 mg/kg | i.v. | 1 h infusion | 1 mg/mL | 326.4 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MHC-matched rhesus monkeys (Naive, captive bred, 3.8-9.6 k) were grafted on the inter-scapular area with circular MHC-mismatched rhesus skin (2 cm, lower abdomen)[1].
-
Dosage:50 mg/kg
-
Administration:i.v., day 0, day 5 and day 12 at a speed of 1.5 ml/kg/h over 1 h, and then collected grafts and blood samples1.
-
Result:Extended graft survival to days 11, 13 and 14 (median day 13) compared vehicle-treatment (complete skin rejection on day 9.5).
Notably delayed necrosis of allogeneic grafts while the vehicle treated grafts showed complete necrosis since day 9.
Alleviated inflammation and inhibited multifocal epithelial hyperplasia with focal para-keratosis, and intra-epidermal infiltrates on epidermis. Potently antagonizes IL-2 in both CD25+ and CD25- cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Plater-Zyberk C, et al. The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transpl Immunol. 2011 Sep; 25(2-3):133-40. [Content Brief]
[2]. Volkland J, et al. A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. Mol Immunol. 2007 Mar; 44(7):1743-53. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MT204 Related Classifications
HY-P991270 Related Classifications
Powered by Bioz